The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Clinical Trial Data Provides Insight into Muscle Biology, Myositis, Myopathies

Clinical Trial Data Provides Insight into Muscle Biology, Myositis, Myopathies

March 20, 2017 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF
design36/shutterstock.com

design36/shutterstock.com

WASHINGTON, D.C.—Ongoing investigation into the disease mechanisms of inflammatory myopathies is generating needed information for the development of potential future therapeutic targets, and current data from clinical trials have shed light on myopathy concerns in different cohorts of patients. These issues were all discussed in a session titled Muscle Biology, Myositis, and Myopathies I during the 2016 ACR/ARHP Annual Meeting.

You Might Also Like
  • ACR 2013 State-of-the-Art Clinical Symposium: How to Identify Signs of Myositis and Metabolic Myopathies
  • Letters: More Tools for Inflammatory Myopathies
  • Myopathies
Explore This Issue
March 2017
Also By This Author
  • Phase 2 Results for Mavrilimumab Are In

Learning in the Lab

Joseph LaConti, MD, PhD, Rheumatology Fellow, Jackson Memorial Hospital, University of Miami, opened the session describing ongoing research on the disease mechanisms underlying anti-synthetase syndrome—a syndrome encompassing a clinical spectrum of diseases including myositis, interstitial lung disease, Raynaud’s phenomenon, symmetric non-erosive arthritis, mechanic’s hand and fever.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Building on previous research that showed a correlation between disease activity and reactivity of serum anti-Jo-1 antibodies (antibodies that target histidyl-tRNA synthetase [HRS]) to the full-length recombinant HRS, Dr. LaConti described current research conducted to refine this correlation through a more detailed examination of antibody binding to subfragments of the HRS protein in order to discover new antibody epitopes associated with defined clinical manifestations.

According to Dr. LaConti, the study revealed a more precise epitope for Jo-1 antibody. Specifically, the study found an increased binding of the Jo-1 antibody to portions of the N terminus of the protein in patients with inflammatory myopathy and Jo-1 antibodies.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In addition, the study found that patients with either joint swelling or Raynaud’s disease had a higher binding affinity of Jo-1 antibodies for these more precise epitopes compared to patients who did not.

“The current study suggests that more specific epitope recognition patterns may be linked to particular clinical features of the anti-synthetase syndrome, providing the rationale for future longitudinal studies relevant to disease prognosis,” said Dr. LaConti.

Inflammatory Myopathies

Further research on the disease mechanisms behind idiopathic inflammatory myopathies was described by Ana Barrera, MD, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, who presented data from a study looking at the role of pathogenic cytokines in disease development.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Building on previous data showing a high prevalence of anti-Ro52/TRIM21 antibodies in patients with myositis, Dr. Barrera and colleagues assessed whether there is a differential production of cytokines associated with Ro52/TRIM 21 levels in patients with recent onset idiopathic inflammatory myopathies.

The study found that Ro52/TRIM 21 levels were decreased in different cellular subsets of patients with idiopathic inflammatory myopathies, said Dr. Barrera, adding that this decrease is associated with defective ubiquitination and proinflammatory cytokine synthesis. However, the study found no correlation between Ro52/TRIM 21 levels and anti-Ro52/TRIM21 autoantibodies.

Pages: 1 2 3 | Single Page

Filed Under: Meeting Reports, Systemic Inflammatory Syndromes Tagged With: 2016 ACR/ARHP Annual Meeting, American College of Rheumatology, anti-synthetase syndrome, Clinical, data, Inflammatory Disease, muscle, Myopathies, myositis, Research, Rheumatic Disease, studyIssue: March 2017

You Might Also Like:
  • ACR 2013 State-of-the-Art Clinical Symposium: How to Identify Signs of Myositis and Metabolic Myopathies
  • Letters: More Tools for Inflammatory Myopathies
  • Myopathies
  • Myositis Autoantibodies as Biomarkers

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)